ESMO 2023

Breast Cancer

Benefit of pembrolizumab in TNBC remains after 5 years of follow-up  

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2023

18 December, 2023 15:50

Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer

Presented By

Dr Fatima Cardoso, Champalimaud Clinical Centre, Portugal

Trial

Phase 3, KEYNOTE-756 trial

Conference

ESMO 2023

18 December, 2023 15:48

Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk

Presented By

Prof. Béatrice Fervers, Centre Léon Bérard, France

Conference

ESMO 2023

18 December, 2023 15:45

Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy

Presented By

Dr Aditya Bardia, Massachusetts General Hospital, USA

Trial

Phase 3, TROPION-Breast01

Conference

ESMO 2023

18 December, 2023 15:41

Colorectal Cancer

Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer

Presented By

Dr Yara Verschoor, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE-3

Conference

ESMO 2023

18 December, 2023 16:04

Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, CodeBreak300

Conference

ESMO 2023

18 December, 2023 16:01

Postoperative ctDNA predicts survival in colorectal cancer

Presented By

Dr Yoshiaki Nakamura, National Cancer Centre Hospital East, Japan

Trial

GALAXY

Conference

ESMO 2023

18 December, 2023 15:55

Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen 

Presented By

Prof. Cornelis J. Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ESMO 2023

18 December, 2023 15:53

Lung Cancer

Perioperative nivolumab boosts event-free survival in NSCLC

Presented By

Dr Tina Cascone, MD Anderson Cancer Center, USA

Trial

Phase 3, CheckMate 77T

Conference

ESMO 2023

19 December, 2023 09:56

Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC

Presented By

Prof. Herbert Ho Fung Loong, Chinese University of Hong Kong, China

Trial

Phase 3, LIBRETTO-431

Conference

ESMO 2023

19 December, 2023 09:54

Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC  

Presented By

Dr Aaron Lisberg, University of California Los Angeles, USA

Trial

Phase 3, TROPION-LUNG01

Conference

ESMO 2023

19 December, 2023 09:51

First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC

Presented By

Prof. Nicolas Girard, Institut du Thorax Curie-Montsouris, France

Trial

Phase 3, PAPILLON

Conference

ESMO 2023

19 December, 2023 09:47

Upper Gastro-Intestinal Cancer

Perioperative durvalumab/FLOT improves pCR in gastric cancer

Presented By

Prof. Salah-Eddin Al-Batran, Northwest Hospital Frankfurt, Germany

Trial

Phase 3, MATTERHORN

Conference

ESMO 2023

19 December, 2023 10:58

Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer

Presented By

Dr Berend van der Wilk, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, SANO

Conference

ESMO 2023

19 December, 2023 10:48

FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer

Presented By

Prof. Bas Groot Koerkamp, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, PREOPANC-2

Conference

ESMO 2023

19 December, 2023 10:35

Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma

Presented By

Prof. Aziz Zaanan, Université Paris Cité, France

Trial

Phase 3, GASTROFOX

Conference

ESMO 2023

19 December, 2023 10:30

Melanoma

Lifileucel induces a durable response in heavily pretreated mucosal melanoma

Presented By

Dr Evidio Domingo-Musibay, Masonic Cancer Center, USA

Trial

Phase 2, C-144-01

Conference

ESMO 2023

19 December, 2023 11:15

Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma

Presented By

Dr Meridith McKean, Tennessee Oncology, USA

Conference

ESMO 2023

19 December, 2023 11:06

Genito-Urinary Cancers

Two potential new first-line standards of care in metastatic urothelial cancer

Presented By

Prof. Thomas Powles, Queen Mary University of London, UK

Trial

Phase 3, EV-302/KEYNOTE-A39; CheckMate 901

Conference

ESMO 2023

19 December, 2023 12:19

LuPSMA and enzalutamide: a promising combination

Presented By

Prof. Louise Emmet, St Vincent’s Hospital Sydney, Australia

Trial

Phase 2, ENZA-p

Conference

ESMO 2023

19 December, 2023 12:15

No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy

Presented By

Prof. Arlene Siefker-Radtke, MD Anderson Cancer Centre, USA

Trial

Phase 3, THOR

Conference

ESMO 2023

19 December, 2023 11:20

Gynaecological Cancers

Featured Interviews

Can radiotracers predict response to PD-L1 inhibitors in early NSCLC?

Expert

Prof. Gary Cook, King's College London and Guy's and St Thomas Hospitals, UK

Conference

ESMO 2023

20 November, 2023 16:01

The importance of detecting early NSCLC

Expert

Prof. Witold Rzyman, Medical University of Gdańsk, Poland

Conference

ESMO 2023

20 November, 2023 15:34